RJA
HARP

Raymond James & Associates’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Raymond James & Associates’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,308
Closed -$392K – 3903
2020
Q3 		$392K Buy
+2,308
New +$333K ﹤0.01% 2794

Other funds holding HARP

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James & Associates's HARP Position: Q4 2020 in Review

Raymond James & Associates sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q4 2020, closing a stake of 2,308 shares — an estimated $392K sold.

Raymond James & Associates first reported a position in HARP in Q3 2020 and held it in 1 quarter. The position peaked at $392K in Q3 2020. 77 funds tracked by Wall St. Rank hold HARP as of Q4 2020.

  • Raymond James & Associates reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Raymond James & Associates sold 2,308 Harpoon Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $392K.
  • Raymond James & Associates first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Raymond James & Associates's Harpoon Therapeutics, Inc. Common Stock position peaked at $392K in Q3 2020.
  • 77 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Raymond James & Associates's 13F filing for Q4 2020, filed 12 Feb 2021.